Lumito Arrow right Arrow right


SCIZYS by Lumito

Lumito’s product solution, SCIZYS by Lumito, consists of a scanner and UCNP reagents (Upconverting Nano Particles coloring liquids).

SCIZYS offers researchers in pathology an extended opportunity for multiplexing by contributing an “invisible” immunohistochemical channel that does not affect the visualization of the morphology of tissue or other chromogen-based IHC stains in the tissue. The more markers imaged, the more specific information is obtained for the particular case.

New tissue images presented at the European Congress of Pathology (ECP) in Basel in September 2022 show that with Lumito’s technology, it is possible to detect protein expression in specific tissue structures.

The ambition is to product launch during the first part of 2023 in the research laboratories segment.



Tissue images showing protein expression 

A. Hematoxylin (morfologi)                                               B. CDH1 with UCNP                                                                              C. CDH1 with UCNP Hematoxylin

The images above, A-C, show that with Lumito’s technology it is possible to demonstrate protein expressions in specific tissue structures, such as skin. This may be important in research in the analysis of skin cancer or inflammatory diseases.

Image A shows core coloring using hematoxylin.

Image B and C show the same hematoxylin image but in combination with a visualization of the CDH1/E-cadherin protein where SCIZYS’ reagents act as a reporter for the protein. Image B and C have been colored digitally in different ways.


Immunostaining of synaptic structures

Image 1                                                                                                                        Image 2

Image 1 above shows the immune staining of synaptic structures in the cerebral cortex. SCIZYS’ reagents act as a reporter for synaptophysin, SYP1 (green). The cell nuclei are visualized using hematoxylin as shown in blue.

Image 2 shows a detail from Image 1 in magnification where the gradient of SYP1 is made more detailed. The protein is used as a biomarker for tissue damage in the brain.



Higher analysis quality and shorter analysis times

The technology enables obtaining images with higher contrast, increased dynamic range, and reduced nonspecific background. Because higher analysis quality and shorter analysis times can be obtained, there are conditions for significantly improving the analysis of tissue samples.

It is also possible to switch between visualization of morphology and our unique UCNP IHC marking. The flexibility of the system also allows visualization of both readings simultaneously, superimposed in the same image. All in all, this provides more detailed information, without the problems of overlapping and non-specific marking obtained with traditional methodology.

Lumito, under the leadership of university lecturer Daniel Öhlund, has recently completed a feasibility study together with Umeå University with good results. The research group has identified how the company’s UCNP technology can be used to improve the ability to visualize protein expressions in pancreatic cancer.


“Using Lumito’s imaging technology, we have investigated, among other things, whether a certain protein spreads via secretion from the cancer cells to the tumor’s supporting tissue, the tumor stroma. Lumito’s technology has led to greater possibilities, compared to other immunohistochemical methods, to visualize the penetration of secreted proteins in the tumor stroma”, says Daniel Öhlund.


The images above show the nucleus and HER2 respectively, in exactly the same cells and the same tissue section.


Contact with research groups

We are involved in several ongoing studies and are interested in collaborating with more research groups. This is to map where our product can make the greatest benefit.

If you are interested in discussing a future collaboration and want to know more about our technology, you are welcome to contact our CEO, Mattias Lundin, at, for more information.